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Metal-free catalysisThe diastereoselective, trichlorosilane-mediate reduction of imines, bearing different and removable chi-
ral auxiliaries, in combination either with achiral bases or catalytic amounts of chiral Lewis bases, was
investigated to afford immediate precursors of chiral APIs (Active Pharmaceutical Ingredients). The car-
bon-nitrogen double bond reduction was successfully performed in batch and in flow mode, in high
yields and almost complete stereocontrol. By this metal-free approach, the formal synthesis of rasagiline
and tamsulosin was successfully accomplished in micro(meso) flow reactors, under continuous flow con-
ditions. The results of these explorative studies represent a new, important step towards the develop-
ment of automated processes for the preparation of enantiopure biologically active compounds.
 2017 Elsevier Ltd. All rights reserved.1. Introduction
Rasagiline mesylate (Scheme 1), also known as (R)-(+)-N-
propargyl-1-aminoindan mesylate, is a commercially marketed
pharmaceutically active substance, under the brand name azilect.
The racemic form of the drug was patented by Aspro Nicholas in
the early 1979, and was later found to be indicated for treatment
of Parkinson’s disease (PD), being effective both as monotherapy
in early PD, and as adjunctive in patients with advancing PD and
motor fluctuations.1 This chiral amine is a potent second-genera-
tion propargylamine pharmacophore that selectively and irre-
versibly inhibits the B-form of the monoamineoxidase enzyme
(MAO-B) over type A by a factor of fourteen.2 European drug-
regulatory authorities approved this potent MAO-B inhibitor in
February 2005 and the US FDA in May 2006.3 Although the
S-()-enantiomer of N-propargyl-1-aminoindane still exerts some
neuroprotective properties, the potency of R-(+)-enantiomer
against the MAO-B enzyme is approximately 1000-fold higher.
Different strategies aimed to the preparation of the enantiopure
compound have been explored,4 but, at the best of our knowledge,
a stereoselective organocatalytic approach for the preparation ofrasagiline has never been reported so far. We report here a
metal-free stereoselective strategy for the synthesis of rasagiline
and of an advanced intermediate of another API, tamsulosin, sold
under the trade name flomax as single enantiomer. Active as
antagonist for a1a adrenergic receptor, It is used to treat symp-
tomatic benign prostatic hyperplasia and to treat urinary retention.
Starting from this common precursor, different pharmaceutically
active compounds could be prepared, having as biological targets
different receptors such as cholinesterase and monoamine oxidase
inhibition,5 r-receptors6 and human adenosine A2A receptor.7
The synthetic plan for the preparation of the two-target mole-
cules involves a metal-free stereoselective reduction of imines,
easily prepared starting from commercially available ketones
(Scheme 1).82. Results and discussions
We initially explored the possibility to use a catalytic amount of
chiral Lewis base (LB) for the stereoselective, trichlorosilane-medi-
ated reduction of the imine prepared starting from 1-indanone.
Two different chiral picolinamides, previously developed in our
group, were tested.9,10 Using ephedrine-derived catalyst A, the chi-
ral amines were obtained in high yields, both using PMP (param-
ethoxyphenyl) and benzyl protected imines, but with modest
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Scheme 1. Synthetic strategy for the synthesis of rasagiline and tamsulosin.
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ter results were observed with catalyst type B, that is known to
lead to the formation preferentially of the (S)-isomer (see
Scheme 2).10
Then, we decided to explore the use of a chiral auxiliary, by
employing a-methylbenzylamine as cheap and readily removable
element of stereocontrol in the reduction, that was already suc-
cessfully employed in previous works (Scheme 3).8j As achiral
Lewis base, N,N-dimethyl formamide was selected as well
established, inexpensive and efficient activator of trichlorosilane
for the reduction of ketoimines.8j,9
Reductions were performed starting from a diastereoisomeric
mixture of imine 3, prepared from 1-(R)-phenylethylamine in a
9:1 (3c:3d) ratio, in favor of the E imine 3c. The best results were
achieved working at 20 C, and performing the reaction for
36 h; the product was obtained in 55% yield and 98:2 diastere-
omeric ratio in favor of the (R,R) stereoisomer 4c (Table 1, entry
5). To achieve complete conversion higher reaction temperature
were needed (Table 1, entry 6), leading to a small decrease of
diastereoselection (90:10 of d.r.).
Finally, in the attempt to increase further the efficiency of the
process, the use of a match combination between the chiral auxil-
iary and the chiral catalyst was investigated. Based on previous
works,9 we selected the known favorable combination of catalyst
A and 1-(R)-phenylethylamine as chiral auxiliary: the reduction
was accomplished in 90% conversion and a 90:10 of d.r. ratio
(Table 1, entry 7). Since the use of catalyst B, that leads to forma-
tion of products of (S) configuration,10 afforded, as expected, the
product in lower stereoselectivity (entry 8, mismatch couple with
the chiral auxiliary that favours the formation of product with (R)LB* (0.15 eq), HSiCl3 (4 eq.)
DCM, -20° C, 18 h
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Scheme 2. Enantioselective reductions of iminesconfiguration), the use of pseudo-enantiomer of catalyst B allowed
to obtain the product 4c in 80% conversion and a complete dias-
teroselectivity (Table 2, entry 9).
With the best reaction conditions in our hands, we decided to
explore the possibility of employing different chiral auxiliaries.
Since the removal of the a-methylbenzylamine tipycally requires
palladium catalysts,11 we focused our attention onto the use of a
chiral auxiliary removable without the need of precious
transition metals. In particular, we selected commercially available
(R)-4-methoxy-a-methylbenzylamine and (R)-2-methyl-2-
propanesulfinamide since they could be removed under metal-free
conditions.12,13
Imines 5a and 6a were readily synthesized and their reduction
was performed in the presence of 3.5 mol eq. of trichlorosilane and
stoichiometric amounts of DMF or catalytic amounts of chiral
picolinamide A (see Scheme 4).
Imine 5a was efficiently reduced using DMF as achiral LB
(Table 2, entry 1), with high conversion (80%) and a complete dias-
teroselectivity. In order to increase the yield, the reaction was then
performed in the presence of catalyst A (Table 2, entry 2); complete
conversion of the starting material into the chiral amine 5b and a
total stereocontrol of the reaction were observed.
Analogously, the reduction of imine 6a was efficiently
promoted by catalyst A, affording the product 6b, that was in situ
deprotected during the basic aqueous work up, to afford the pri-
mary chiral amine 1 in quantitative yield and 60% e.e. (entry 4,
Table 2).
Considering the raising interesting for the flow preparation of
API’s,14 based on these results and with the aim to further
accelerate the reaction, we explored the possibility of developing∗
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Scheme 3. Stereoselective reductions of chiral imines 3c/3d.
Table 1
Reductions of chiral imine 3c/3d.
Entry LB T (C) t (h) Conv. (%)a d.r.b
1 DMF 0 18 67 90:10
2 DMF 10 18 44 90:10
3 DMF 10 36 42 90:10
4c DMF 0 36 77 90:10
5c DMF 20 36 55 98:2
6 DMF 0 to rt 18 98 90:10
7d A 20 36 90 90:10
8d B 20 36 20 76:24
9d,e B 20 36 80 >98:2
a Conversions were evaluated on 1H NMR.
b d.r. were evaluated on crude mixtures using 1H NMR.
c HSiCl3 was further added every 12 h.
d Reaction was performed using 0.15 eq. of chiral LB.
e Reaction was promoted by the pseudoenantiomer of catalyst B.
Table 2
Reduction of chiral imines 5a-6.
Entry Imine LB Conv. (%) d.r.
1a 5a DMF 80 >98:2
2b 5a A 98 >98:2
3a 6a DMF <5 ND
4c 6a A 99 80:20
a 5 eq. of DMF were used.
b 0.15 eq of catalys were used.
c The product was obtained as primary amine directly after the work up; e.e. was
determined by HPLC on chiral column (see the Supporting Information).
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Scheme 4. Stereoselective reductions of chiral imines 5a-6a.
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Recently our group has demonstrated that HSiCl3-mediated
diastereoselective imine reduction could be efficiently performed
in (micro)-mesoreactors under continuous flow conditions.15The experimental set up involves a coil-reactor, realized by
using PTFE tubing (1.58 mm outer diameter, 0.58 mm inner diam-
eter, 1.89 m length, 500 lL effective volume) coiled in a bundle and
immersed in a bath cooled to the desired temperature. A syringe
pump, equipped with two Hamilton gastight syringes, fed the
solution containing the imine and the Lewis base dissolved in
DCM, and the solution of trichlorosilane in DCM through a T-junc-
tion into the coil-reactor (Scheme 5).
Running the reduction of imine 5a at low temperature (17 C),
low conversions were detected; when the reaction was performed
at 30 C, the product was isolated in 83% yield but, as expected,
with a lower disatereoisomeric ratio (92:8, entry 4, Table 3). In
order to achieve a complete stereocontrol, the reaction was run
in the flow reactor in the presence of catalyst A; operating at
30 C and with a 30 min residence time, the matching combination
of an enantiopure catalyst with the chiral auxiliary, the chiral
amine 5b was in continuo produced in 70% yield as stereoisomer-
ically pure compound (entry 5, Table 3).
The synthesis of an advanced intermediate of tamsulosin was
then studied. By following the same synthetic approach and taking
advantage of the previously used chiral auxiliaries, enantiopure
imines 7a and 8a were synthesized and their reduction studied
in batch (Scheme 6).
The results are reported in Table 4; when using an achiral base
(DMF), the reduction of imine 7a proceeds with a modest diastere-
oselectivity, and only with catalyst B an improved stereocontrol
was obtained, although the product was isolated in 50% yield only.
However, starting from chiral imine 8a better results were
achieved; simply using a combination of two very cheap reagents,
like trichlorosilane and N,N-dimethylformamide, the primary
amine 2 was directly obtained after the work up in quantitative
yield and 94% e.e. (entry 9, Table 4).
The reaction was then performed in the previously described
flow reactor system (Scheme 7); with imine 7a the in-flow reduc-
tion nicely reproduced the results of the in batch procedure
(entries 1–2, Table 5); interestingly, it was possible to achieve
the removal of the chiral auxiliary under continuous flow
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Scheme 5. Continuous flow preparation of an advanced precursor of rasagiline.
Table 3
In-flow synthesis of an advanced intermediate of rasagiline.
Entry LB Imine T (C) Residence time (min) Eq. Conv. (%) d.r.
1 DMF 5a 17 10 5 20 98:2
2 DMF 5a 17 20 5 34 98:2
3 DMF 5a 17 30 5 35 98:2
4 DMF 5a 30 20 5 83 92:8
5 A 5a 30 20 0.2 70 >98:2
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Scheme 6. In batch synthesis of advanced precursors of tamsulosin.
Table 4
In batch synthesis of tamsulosin precursor.
Entry LB Imine Eq. Conv. (%) d.r.
1a DMF 7a 5 99 65:35
2b DMF 7a 5 99 70:30
3 DMF 7a 5 99 77:23
4 A 7a 0.15 <5 n.d.
6 B 7a 0.15 50 92:8
7 A 8a 0.15 <5 n.d.
8 B 8a 0.15 45 n.d.
9c DMF 8a 0.15 99 93:7c
a Reaction performed from 0 C to room temperature.
b Reaction performed at 0 C.
c The product was obtained as primary amine directly after the work up; e.e. was determined by HPLC on chiral column (see the Supporting Information).
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hydrogenolysis of chiral amines was performed with a Thales-
Nano H-Cube MiniTM, equipped with a 10% Pd/C cartridge; at
50 C and 50 bar, after 1 h, chiral amine 2 was obtained in quan-
titative yield.When enantiopure imine 8a was reduced with DMF and
trichlorosilane in the PTFE flow reactor, the chiral primary amine
2 was directly produced and was collected out from the flow reac-
tor, after in line basic aqueous work up, in 70% isolated yield and
88% e.e. (entries 3–4, Table 5).
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Scheme 7. In-flow synthesis of chiral amine 2, a tamsulosin precursor.
Table 5
Continuous flow reduction of chiral imines 7a and 8a.
Entry LB Imine Residence time (min) Eq. Conv. (%) d.r.
1 B 7a 20 0.2 60 92:8
2 B 7a 30 0.2 75 92:8
3a DMF 8a 20 5 60 94:6a
4a DMF 8a 30 5 70 94:6a
a The product was obtained as primary amine directly after the work up; e.e. was determined by NMR with chiral shift-agents (see the Supporting Information).
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In the present study, a stereoselective, metal-free strategy for
the synthesis of chiral amines, direct precursors of rasagiline and
tamsulosin, was developed. After setting up the reaction conditions
in batch, the stereoselective trichlorosilane-mediated reduction of
chiral imines was efficiently performed under continuous flow
conditions. Chiral primary amines were obtained either by a con-
tinuous flow hydrogenolysis, or directly out from the flow reactor
after an in-line aqueous work up, depending on the chiral auxiliary
group at the amine nitrogen atom.
The present work represents a further step towards the devel-
opment of a multistep continuous flow process for the synthesis
of enantiomerically pure pharmaceutically relevant amines.Acknowledgements
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